Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

James Combs

Surgery Newnan, GA Medical Doctor

NPI 1548418684 CMS profile 252084

775 Poplar Rd, Suite 260, Newnan, GA 30265

Open in the dashboard

General payments

$5,809

260 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, James Combs of Newnan, GA is reported in the CMS Open Payments database as having received $5,809 across 260 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 71st percentile of Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $982 30
2024 General $946 29
2023 General $1,011 49
2022 General $957 57
2021 General $770 49
2020 General $501 23
2019 General $642 23

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Combs
  • Surgery median
  • Middle half of Surgery
  • National median

In program year 2025, general payments to James Combs were reported at $982. Among 17,702 Surgery profiles paid that year, the median was $280 and the middle half received between $91 and $1,259.

Show as a table
Year James Combs Surgery median Middle half National median
2019 $642 $253 $82–$1,521 $163
2020 $501 $131 $40–$706 $114
2021 $770 $168 $50–$904 $132
2022 $957 $224 $76–$1,218 $149
2023 $1,011 $253 $82–$1,255 $160
2024 $946 $279 $90–$1,381 $164
2025 $982 $280 $91–$1,259 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. W. L. Gore & Associates, Inc. $1,871 70 payments
  2. Philips Electronics North America Corporation $639 16 payments
  3. Medtronic, Inc. $618 49 payments
  4. Boston Scientific Corporation $420 12 payments
  5. Janssen Pharmaceuticals, Inc $411 25 payments
  6. Cardiva Medical, Inc. $296 6 payments
  7. Cook Medical LLC $262 10 payments
  8. LeMaitre Vascular, Inc. $203 7 payments
  9. Medtronic Vascular, Inc. $202 12 payments
  10. Pfizer Inc. $130 6 payments
  11. Other $759 47 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,809 260 payments
Products named General payments · program years 2019–2025
  1. GORE VIABAHN VBX Balloon Expandable Endo $1,164 28 payments
  2. XARELTO $411 25 payments
  3. (9281) Turbo Elite $330 7 payments
  4. GORE VIABAHN Endoprosthesis with Heparin $310 24 payments
  5. Cardiva VASCADE 6/7F VCS $296 6 payments
  6. GORE PROPATEN Vascular Graft $197 3 payments
  7. ENDURANT IIS $187 14 payments
  8. Endurant $158 10 payments
  9. VENASEAL $157 8 payments
  10. ELIQUIS $130 6 payments
  11. Other $2,900 184 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

466

Median for Vascular Surgery: 122

Drug cost

$116,612

Median for Vascular Surgery: $14,135

Branded share of claims

80.9%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 67 $84,526
Xarelto Rivaroxaban Brand 20 $28,710
Cilostazol Generic 42 $1,135
Clopidogrel Clopidogrel Bisulfate Brand 97 $697
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 135 $623
Gabapentin Generic 16 $468
Lidocaine-Prilocaine Lidocaine/Prilocaine Brand 14 $203
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 44 $191
Warfarin Sodium Generic 14 $41
Prednisone Generic 17 $19

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 79 billing codes

Paid by Medicare

$255,363

Of which drugs: $939

Medicare patients

496

Average age 73

Services billed

3,324

252 women, 244 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 55%
Diabetes 53%
Ischemic heart disease 50%
Arthritis 48%
Heart failure 42%
COPD 28%
Atrial fibrillation 27%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 42 2,232 $233

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

260 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgery in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record